Nasdaq

Solid Biosciences to Initiate Phase 1b Trial for SGT-501, a Novel Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia

Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...
Seeking Alpha

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and ...
Seeking Alpha

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
Medical Xpress

Polymorphic Catecholaminergic Ventricular Tachycardia

Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in electrical potential when cells become excited—and calcium transients—calcium ...
Medical Xpress

Polymorphic Catecholaminergic Ventricular Tachycardia

Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated production of 3D cardiac ...